Dual therapy stent (DTS) is considered as a next step evolution in stent designing. The first DTS was implanted in 1999, involved in performing function such as accelerated vessel healing and inhibiting cell proliferation. The stent is made through the addition of bone marrow-derived CD34þ endothelial progenitor cell capture system on the luminal stent surface. DTS provides better advantages over other stents such as it offers lower rates of in-stent restenosis and entails subsequent medical interventions.
Furthermore, rising prevalence of coronary artery disorders, growing geriatric population prone to various arterial disorders, technological advancements in DTS is propelling the market growth of dual therapy stents. However, reducing price of drug eluting stent and availability of alternative therapeutic procedures is hindering the market growth of dual therapy stents market.
The global dual therapy stents market is expected to grow at a CAGR of around 4.1% over the period of next 5 years.
Get a brochure of this research study Click Here
The market growth dual therapy stents is driven by key factors such as rising ageing population suffering from various arterial disorders. According to the data published in Journal of Geriatric Cardiology on 2016, incidence and prevalence of aortic disease, and venous thromboembolism (VTE) increase as age-related alterations in vascular structure, peripheral arterial disease (PAD), and function are combined by longer exposure to cardiovascular disease (CVD) risk factors among older population. According to a published article in Mesimedical in August 2019, CVDs is responsible for about a quarter of death in India. Approximately 80% of death is due to CAD (Coronary Artery Disease). More then 200 million people have PAD globally, with a spectrum of symptoms from none to severe based on the published article in PubMed in August 2018.
Furthermore, new therapeutic intervention focused on dual therapy stent is further driving the market growth. For instance, in 2017, the safety and efficacy of the COMBO dual therapy stent in patients with acute ST-elevation myocardial infarction (STEMI) was studied and the study was published in Clinical Research article which showed acceptable rate and positive outcome. Such studies are contributing towards the market growth of DTS. Therefore, such studies are bolstering the demand for dual therapy stents and projected to increase its demand in the near future.
DUAL THERAPY STENTS MARKET SEGMENTATION:
By Usage Type:
- Single use
- Multi use
By End User:
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
North America is projected to gain dominance in the dual therapy stents market. The market growth in this region can be attributed to well established healthcare infrastructure, increasing number of geriatric population, rising prevalence of atherosclerosis due to unhealthy lifestyle and obesity and established market players involved in new launch, acquisition, strategic collaboration. For instance, in March 2021, the B. Braun Interventional Systems (BIS) Company has announced to collaborate with Infraredx on a trial for the B. Braun SeQuent Please ReX. Thus, this collaboration is expected to drive the market growth of dual therapy stent market in this region. In addition, presence of well established players in the market and R&D sector is further boosting the market growth in this region.
Asia Pacific drug therapy stent is anticipated to exhibit the fastest growth in the coming years. The market growth is due to rising pool of patients suffering from arterial disorders such as CVD, increasing old age population suffering from coronary disease, rising adoption of DTS technology for the cure of such diseases is contributing towards the market growth. For instance, according to the published article in 2021, Hong Kong is recorded the second highest incidence for stroke in the Asia-Pacific region with 314 per 100,000 population after China (403 in 100,000 population.
Moreover, the incidence rate of ischemic heart disease, including heart attacks, is at the peak level Hong Kong due rapidly growing ageing population, increasing obese population, sedentary lifestyle. These factors are driving the market growth in this region.
FEW KEY PLAYERS IN DUAL THERAPY STENTS MARKET:
- Medtronic plc
- Ostial Corporation
In September 2020, OrbusNeich Medical Co. Ltd. declared that the National Medical Products Administration (NMPA) granted market approval for the Combo Bio-Engineered Sirolimus Eluting Stent in China. It is one of the first dual therapy stent that includes accelerating endothelial coverage and control neointimal proliferation through the mixture of the proven pro-healing technology with an abluminal sirolimus drug elution produced from a biodegradable polymer.
In April 10, 2019 BIOTRONIK declared United States (US) commercial launch of the PK Papyrus covered coronary stent system. The stent is being used in the emergency situation for acute coronary perforations. Approximately, 800,000 percutaneous coronary intervention procedures are performed every year and approximately 8,000 require a covered stent, classifying PK Papyrus as a Humanitarian Use Device. The stent is made of single-stent design, ultrathin strut, and unique electrospun polyurethane membrane. This enhances the treatment options and is designed to reduce the rising adverse outcomes associated with coronary artery perforations. Such launch by the established companies in the market is driving the market growth of dual therapy stents.